NASDAQ | VICL: 1.29  +0.04

Vical Provides Company Update at Biocom's Global Life Science Partnering Conference


SAN DIEGO, Feb. 24, 2017 (GLOBE NEWSWIRE) -- Vical Incorporated (Nasdaq:VICL) today announced that the company will provide an overview of its technologies, development programs, and outlook at 2:15 p.m. PT on Thursday, March 2, at Biocom's Global Life Science Partnering Conference (La Jolla – March  1-2). A copy of the presentation will be available through the Events & Presentations page in the Investors section of the Vical website at

About Vical
Vical develops biopharmaceutical products for the prevention and treatment of chronic or life-threatening infectious diseases, based on its patented DNA delivery technologies and other therapeutic approaches. Additional information on Vical is available at

Tony Ramos
(858) 646-1127

Primary Logo

Source: Vical Incorporated

P. 858 646 1100 10390 Pacific Center Court, San Diego, California 92121
Designed by Mentus
This link to a non-Vical website is provided as a resource. Vical assumes no responsibility for content not provided by Vical, or for practices or standards of any non-Vical websites.